Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure
We have summarized the pathophysiological processes of neurodegenerative diseases, cerebrovascular disorders, neuroinflammation, brain tumors, and psychiatric conditions, along with the mechanisms of lactylation modifications involvement
[PubMed] [Google Scholar] 317
GLP-1 agonists, such as Trulicity (dulaglutide), also provide cardiovascular protection and are FDA-approved to reduce the risk of major cardiovascular events in diabetes patients with heart disease or related risk factors
Hypovitaminosis D in bariatric surgery: a systematic review of observational studies
It's encouraging to see the FDA expand treatment options for obesity and cardiovascular health